Showing results for 
Search instead for 
Did you mean: 

Mass spectrometry-based proteomics in preclinical drug discovery

Reputable Mentor II
Reputable Mentor II
Schirle M, Bantscheff M, Kuster B.
Chem Biol. 2012 Jan 27;19(1):72-84.
Preclinical stages in the drug discovery process require a multitude of biochemical and genetic assays in order to characterize the effects of drug candidates on cellular systems and model organisms. Early attempts to apply unbiased proteomic techniques to the identification of protein targets and off-targets as well as to elucidate the mode of action of candidate drug molecules suffered from a striking discrepancy between scientific expectations and what the technology was able to deliver at the time. Dramatic technological improvements in mass spectrometry-based proteomic and chemoproteomic strategies have radically changed this situation. This review, therefore, highlights proteomic approaches suitable for preclinical drug discovery illustrated by recent success stories.
Novartis Institutes for BioMedical Research, Inc., Cambridge, MA 02139, USA.
Version history
Last update:
‎10-15-2021 11:51 AM
Updated by: